MannKind Corp (MNKD): Total Liabilities
$843.20M
As of 2025-12-31
$799.50M
As of 2026-06-30
+15.6%
3-year compound annual growth
+23.9%
5-year compound annual growth
+5.9%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $843.20M | +78.4% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $472.66M | -34.5% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $721.37M | +32.2% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $545.82M | +2.9% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $530.51M | +83.6% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $289.03M | +1.7% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $284.25M | +0.5% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $282.79M | -5.5% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $299.31M | +3.0% | 2019-02-26, Balance as of period end |
| 2016-12-31 | $290.66M | -39.0% | 2018-02-27, Balance as of period end |
| 2015-12-31 | $476.74M | +1.8% | 2017-03-16, Balance as of period end |
| 2014-12-31 | $468.21M | +61.8% | 2016-03-15, Balance as of period end |
| 2013-12-31 | $289.36M | -20.1% | 2015-03-02, Balance as of period end |
| 2012-12-31 | $361.99M | -29.5% | 2014-03-03, Balance as of period end |
| 2011-12-31 | $513.21M | +10.9% | 2013-03-18, Balance as of period end |
| 2010-12-31 | $462.79M | n/a | 2012-03-15, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| MannKind Corp (MNKD) | 2025-12-31 | $843.20M | +78.4% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $243.49M | +27.3% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $2.15B | +5.0% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $420.83M | n/m |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $334.65M | +27.5% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $248.97M | +9.7% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $369.84M | +4.9% |
| Harrow, Inc. (HROW) | 2025-12-31 | $347.39M | +8.7% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $509.73M | +128.3% |
Compare MNKD, ARQT, SVA, CRMD side by side · Screen every company in Pharmaceutical Preparations ↗